Antiviral Medicines — Philippines, South Africa, Australia & Singapore | Tafero EM · Resof L · Spegr

 FAQ 1: How does the Philippines' PhilHealth insurance system cover HIV and HBV antivirals and where does Unnati Pharmax fill gaps?

The Philippines' national health insurance programme — PhilHealth — provides partial coverage for hospitalisation and some outpatient treatments, but HIV and HBV antiviral medication coverage through PhilHealth remains inconsistent and heavily dependent on which hospital or treatment hub the patient attends. The Philippine government's HIV treatment programme — administered through the Department of Health's social hygiene clinics and HIV treatment hubs — provides free ART (primarily TLD: Tenofovir+Lamivudine+Dolutegravir) funded through PEPFAR and DOH budgets for Filipino HIV-positive nationals. However, significant coverage gaps persist: the Philippine HIV treatment programme uses a limited formulary — patients who need TAF-based regimens (Tafero EM) for renal or bone reasons, or complete single-tablet regimens like Generic Biktarvy, may not have these available through the public programme; HBV antiviral treatment (Tafsure TAF or Tavin TDF) is not consistently funded through Philippine public health programmes — HBV patients must often self-fund; and Resof L for HCV is not widely available through Philippines' public programme. Unnati Pharmax's antiviral range fills all these Philippine gaps — providing Tafero EM for patients needing TAF-based therapy, Tafsure for HBV treatment, and Resof L for HCV cure — at WHO-GMP certified quality and dramatically reduced private pricing that Filipino patients can realistically afford.

 FAQ 2: How does South Africa's recent HBV treatment guideline update affect demand for Tafsure and Tavin from Unnati Pharmax?

South Africa's Southern African HIV Clinicians Society (SAHCS) updated HBV management guidelines in 2024 to align with WHO's recommendation of TDF as first-line HBV treatment — replacing older agents like Entecavir as the preferred option due to TDF's activity against both HBV and HIV (relevant for the high co-infection rate in SA), low resistance barrier, and generic affordability. South Africa's public sector — through the National Department of Health's Essential Medicines List — lists TDF (Tavin) for HBV treatment alongside its HIV use. For South Africa's estimated 2-5 million people with chronic HBV (prevalence approximately 7-8% of the general population, much higher in specific communities), TDF access through the public sector is improving but remains inconsistent. South Africa's private healthcare sector — where 16% of the population with medical aid access brand or quality-generic HBV medications — provides TAF (Tafsure) as the preferred HBV treatment for medical aid patients where renal or bone concerns are present. Unnati Pharmax's Tafsure and Tavin serve South Africa's private sector HBV patients at dramatically reduced cost versus brand Vemlidy and Viread South African private pharmacy pricing — making modern HBV treatment financially accessible for South Africans managing their HBV privately without the benefit of public sector pricing.

 FAQ 3: How does Australia's PrEP programme compare to Singapore's and what role do generic antivirals play in each market?

Australia and Singapore represent contrasting approaches to HIV PrEP access, reflecting their different healthcare system architectures. Australia's PrEP landscape: PBS-listed TDF+FTC (generic TDF-based PrEP) has been available since 2018, providing affordable daily PrEP at AUD $30/month PBS co-payment for Medicare-eligible Australians; generic Descovy equivalent (TAF-based) is also PBS-available; GP prescribing without specialist referral is standard; and Australia has achieved some of the world's highest PrEP uptake among eligible MSM populations. Singapore's PrEP landscape: Singapore's Ministry of Health approved PrEP in 2019 through the National HIV Programme; PrEP is available at NCID's DSC Clinic and private clinics; not fully subsidised under MediShield Life for all PrEP indications — patients often pay significant out-of-pocket costs at private clinics; and Singapore's high cost-of-living makes full-cost PrEP at private rates (SGD 100-200/month) challenging for lower-income residents. Unnati Pharmax's Generic Descovy and Tafero EM serve: Australian PrEP users who are not Medicare-eligible (international students, working holiday makers) and Singapore PrEP users seeking affordable private supply as an alternative to clinic-dispensed brand Descovy — providing affordable HIV prevention access in both markets where specific populations face significant cost barriers despite both countries' relatively progressive PrEP policies.

 FAQ 4: How does Unnati Pharmax ensure WHO-GMP quality consistency across its antiviral range for all four markets?

Quality assurance for antiviral medicines — HIV antiretrovirals, HBV antivirals, HCV DAAs, and COVID antivirals — is non-negotiable given the clinical consequences of substandard medication: treatment failure, resistance development, and disease progression. Unnati Pharmax's quality assurance framework for all four markets: manufacturer selection — we source exclusively from WHO-GMP certified Indian pharmaceutical manufacturers who have undergone WHO Prequalification or WHO-GMP inspection by recognised national regulatory authorities (TGA Australia, Health Canada, UK MHRA); batch-specific certificate of analysis (COA) — every shipment includes COA confirming active ingredient identity and assay (content), dissolution testing results, impurity profile, and physical characteristics; cold-chain integrity — temperature excursion monitoring for temperature-sensitive antivirals during DHL and FedEx international express transit; and product traceability — batch numbers are recorded at order fulfilment, enabling post-market surveillance if any quality concern emerges. For Philippines customers, WHO Prequalification certificates are specifically relevant — the Philippine FDA recognises WHO Prequalification as an acceptable quality standard for procurement decisions. For Singapore customers, HSA's regulatory framework recognises WHO-GMP certification as a basis for personal importation quality assessment. For Australian and South African customers, TGA's and SAHPRA's respective personal importation frameworks accept WHO-GMP certified products for personal therapeutic use. Unnati Pharmax's quality documentation is available for download at unnatipharmax.com or on request at Unnatipharmax@gmail.com.

 FAQ 5: What new antiviral products is Unnati Pharmax planning to add for Philippines, South Africa, Australia, and Singapore customers in the second half of 2026?

Unnati Pharmax's product expansion programme for the second half of 2026 is driven by customer requests and emerging clinical needs across our four key markets. Planned additions and expansions: Extended COVID antiviral range — as COVID antiviral treatment becomes more routinely integrated into endemic healthcare, Unnati Pharmax is expanding Molnulee availability with larger pack sizes and institutional ordering options for clinic stockists in Philippines, South Africa, and Singapore; HBV treatment expansion — adding Entecavir as a complementary HBV option alongside Tafsure and Tavin for patients where Entecavir is the clinically preferred choice based on specific resistance or tolerability profiles; HCV genotype 3 coverage — evaluating the addition of Sofosbuvir+Velpatasvir (Epclusa generic equivalent) to complement Resof L for Australia's PWID HCV population where GT3 is prevalent; and HIV PrEP starter packs — facilitating initial PrEP access for customers in the Philippines and Singapore where single-month starter supply enables PrEP initiation while long-term PBS or insurance access is being arranged. We also intend to expand our B2B institutional supply relationships — partnering with community health organisations, HIV clinics, and pharmacy networks in Manila, Johannesburg, Cape Town, Sydney, Melbourne, Brisbane, Perth, and Singapore to provide regular volume supply at institutional pricing. Contact Unnatipharmax@gmail.com or WhatsApp +91 82650 41513 to register your organisation's interest in institutional supply partnerships for 2026.